UroGen posts $50.4 million ZUSDURI revenue, cites patent allowance and pipeline progressAug 5Quarterly updatemitomycinUGN-104
UroGen registers Phase 1 dose-escalation trial of UGN-501 in recurrent NMIBCJul 24Trial updateUGN-501UroGen Pharma Ltd.
Sign inSign in